Table 2 subgroup analysis of the included studies for outcome remyelination.

From: Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis

Subgroup

Comparisons

Effect estimate [95% CI]

I2

Overall

110

1.61 [1.26, 1.97]

85%

MS model

Cuprizone

66

1.61 [1.16, 2.07]

83%

Ethidium bromide

16

1.67 [0.68, 2.65]

87%

Lysolecithin

28

1.60 [0.90, 2.30]

86%

Method

Electron microscopy

32

1.73 [1.05, 2.40]

87%

MBP immuno-staining

26

2.16 [1.44, 2.87]

82%

Luxol fast blue

17

1.85 [0.97, 2.73]

79%

H&E lesion area

5

5.17 [2.83, 7.51]

92%

MOG immune-staining

2

3.29 [0.23, 6.35]

85%

Therapeutic regimen

therapeutically

102

1.67 [1.30, 2.04]

84%

  1. The effect estimate was displayed by the standardized mean difference (SMD) and 95% confidence intervals (CIs). No significant differences were found in the subgroup analyses. Abbreviations: MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein.
Back to article page